CN108602803A - 具有抗增殖活性的哌啶并苯并二氮杂*化合物 - Google Patents

具有抗增殖活性的哌啶并苯并二氮杂*化合物 Download PDF

Info

Publication number
CN108602803A
CN108602803A CN201680060201.8A CN201680060201A CN108602803A CN 108602803 A CN108602803 A CN 108602803A CN 201680060201 A CN201680060201 A CN 201680060201A CN 108602803 A CN108602803 A CN 108602803A
Authority
CN
China
Prior art keywords
methyl
oxy
alkyl
methoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680060201.8A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·约瑟夫·马克·杰克逊
大卫·埃德温·瑟斯顿
孔达卡尔·米拉祖尔·拉赫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pheon Therapeutics Ltd
Original Assignee
Femtogenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Femtogenix Ltd filed Critical Femtogenix Ltd
Priority to CN202210543524.XA priority Critical patent/CN114907345B/zh
Publication of CN108602803A publication Critical patent/CN108602803A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN201680060201.8A 2015-08-21 2016-08-19 具有抗增殖活性的哌啶并苯并二氮杂*化合物 Pending CN108602803A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210543524.XA CN114907345B (zh) 2015-08-21 2016-08-19 具有抗增殖活性的哌啶并苯并二氮杂䓬化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1514928.9A GB201514928D0 (en) 2015-08-21 2015-08-21 PDD compounds
GB1514928.9 2015-08-21
PCT/GB2016/052565 WO2017032983A1 (en) 2015-08-21 2016-08-19 Piperidinobenzodiazepine compounds with anti proliferative activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210543524.XA Division CN114907345B (zh) 2015-08-21 2016-08-19 具有抗增殖活性的哌啶并苯并二氮杂䓬化合物

Publications (1)

Publication Number Publication Date
CN108602803A true CN108602803A (zh) 2018-09-28

Family

ID=54292043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680060201.8A Pending CN108602803A (zh) 2015-08-21 2016-08-19 具有抗增殖活性的哌啶并苯并二氮杂*化合物
CN202210543524.XA Active CN114907345B (zh) 2015-08-21 2016-08-19 具有抗增殖活性的哌啶并苯并二氮杂䓬化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210543524.XA Active CN114907345B (zh) 2015-08-21 2016-08-19 具有抗增殖活性的哌啶并苯并二氮杂䓬化合物

Country Status (13)

Country Link
US (1) US10975072B2 (enExample)
EP (2) EP4086251A1 (enExample)
JP (2) JP6903635B2 (enExample)
KR (1) KR102710425B1 (enExample)
CN (2) CN108602803A (enExample)
AU (1) AU2016313228B2 (enExample)
CA (1) CA2996406A1 (enExample)
DK (1) DK3337795T3 (enExample)
EA (1) EA201890539A1 (enExample)
GB (1) GB201514928D0 (enExample)
IL (1) IL257650B (enExample)
MX (1) MX395406B (enExample)
WO (1) WO2017032983A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641910A (zh) * 2016-06-24 2019-04-16 梅尔莎纳医疗公司 吡咯并苯二氮*及其缀合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) * 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) * 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
WO2017201132A2 (en) 2016-05-18 2017-11-23 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
GB201814281D0 (en) * 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2024127333A1 (en) * 2022-12-14 2024-06-20 Pheon Therapeutics Ltd Cytotoxic compounds
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039752A1 (en) * 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
US20080064870A1 (en) * 2006-08-14 2008-03-13 Council Of Scientific & Industrial Research Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
CN102365021A (zh) * 2009-02-05 2012-02-29 免疫基因公司 新型苯并二氮杂*衍生物
WO2015028850A1 (en) * 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5841878A (ja) * 1981-09-07 1983-03-11 Fujisawa Pharmaceut Co Ltd ベンゾジアゼピン誘導体、その製法およびそれを有効成分として含有する抗がん剤
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5418229A (en) 1990-01-06 1995-05-23 Alker; David Muscarinic receptor antagonists
WO1993013777A1 (en) 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy
WO1994022861A1 (en) 1993-04-05 1994-10-13 Pharmaceutical Discovery Corporation PYRIDO[2,3-b][1,4]BENZODIAZEPINONES AS M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
AU5844796A (en) 1995-05-31 1996-12-18 Yamanouchi Pharmaceutical Co., Ltd. Fused benzodiazepinone derivatives and medicinal composition of the same
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
AU758160B2 (en) 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
ES2260570T3 (es) 1998-08-27 2006-11-01 Spirogen Limited Pirrolobenziodiazepinas dimericas.
US6608193B2 (en) 2001-12-21 2003-08-19 The Procter & Gamble Company Methods for synthesis of amino-tetrahydroisoquinoline ring compounds
ES2285227T3 (es) 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
US7456169B2 (en) 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
CA2520901C (en) 2003-03-31 2009-09-08 Council Of Scientific And Industrial Research Pyrene-linked pyrrolo (2,1-c) (1,4) benzodiazepine derivatives useful as anticancer agents
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
WO2005117876A1 (en) 2004-06-01 2005-12-15 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
EP1781300A1 (en) 2004-07-16 2007-05-09 ProteoSys AG Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
IT1362675B (it) 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
WO2008007661A1 (en) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Tricyclic heterocyclic compound and use thereof
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
JP2009263283A (ja) 2008-04-25 2009-11-12 Toray Ind Inc Ｃ型肝炎ウイルス阻害剤
CN102124000B (zh) 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
US20110263574A1 (en) 2009-01-13 2011-10-27 Proteosys Ag Pirenzepine as otoprotective agent
EP2421870B1 (en) 2009-04-23 2016-03-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
CU20090172A7 (es) 2009-10-09 2011-10-05 Ct De Investigación Y Desarrollo De Medicamentos Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
EP2550275B1 (en) 2010-03-22 2014-03-12 Council Of Scientific & Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepine-benzothiazole or benzoxazole conjugates linked through piperazine moiety and process for the preparation thereof
US20130210804A1 (en) 2010-10-25 2013-08-15 Neville J. Anthony Tricyclic mglur5 receptor modulators
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
IN2014MN02092A (enExample) * 2012-04-30 2015-09-04 Spirogen Sarl
AR098743A1 (es) 2013-12-13 2016-06-08 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
GB201407816D0 (en) 2014-05-02 2014-06-18 King S College London Pyrrolobenzodiazepine Compounds
SI3191135T1 (sl) 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
CA2968464A1 (en) 2014-11-25 2016-06-02 Bayer Pharma Aktiengesellschaft Substituted pyridobenzodiazepinone-derivatives and use thereof
WO2016089830A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10442819B2 (en) 2014-12-05 2019-10-15 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
GB201510010D0 (en) * 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) * 2015-08-21 2015-10-07 King S College London PDD compounds
WO2017074914A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
WO2017201132A2 (en) 2016-05-18 2017-11-23 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
US10526294B2 (en) 2016-06-24 2020-01-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2018053552A2 (en) 2016-09-19 2018-03-22 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039752A1 (en) * 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
US20080064870A1 (en) * 2006-08-14 2008-03-13 Council Of Scientific & Industrial Research Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
CN102365021A (zh) * 2009-02-05 2012-02-29 免疫基因公司 新型苯并二氮杂*衍生物
WO2015028850A1 (en) * 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAGULA MARKANDEYA ET AL.: ""Asymmetric syntheses of piperidino-benzodiazepines through ‘cation-pool’ host/guest supramolecular approach and their DNA-binding studies"", 《TETRAHEDRON: ASYMMETRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641910A (zh) * 2016-06-24 2019-04-16 梅尔莎纳医疗公司 吡咯并苯二氮*及其缀合物

Also Published As

Publication number Publication date
US20180291021A1 (en) 2018-10-11
NZ740723A (en) 2024-11-29
IL257650B (en) 2022-06-01
KR102710425B1 (ko) 2024-09-25
EP3337795B1 (en) 2022-06-22
EP3337795A1 (en) 2018-06-27
CA2996406A1 (en) 2017-03-02
JP6903635B2 (ja) 2021-07-14
DK3337795T3 (da) 2022-07-25
KR20180043314A (ko) 2018-04-27
GB201514928D0 (en) 2015-10-07
EP4086251A1 (en) 2022-11-09
MX2018002242A (es) 2018-05-02
CN114907345A (zh) 2022-08-16
MX395406B (es) 2025-03-25
AU2016313228B2 (en) 2020-12-24
WO2017032983A1 (en) 2017-03-02
JP2018525405A (ja) 2018-09-06
AU2016313228A1 (en) 2018-04-12
IL257650A (en) 2018-04-30
CN114907345B (zh) 2025-10-10
EA201890539A1 (ru) 2018-09-28
US10975072B2 (en) 2021-04-13
JP2021152063A (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
CN114907345B (zh) 具有抗增殖活性的哌啶并苯并二氮杂䓬化合物
US12583857B2 (en) Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
JP5116686B2 (ja) Ｃｃ−１０６５類似体の調製方法及び調製用化合物
JP6581630B2 (ja) 新規ベンゾジアゼピン誘導体
CN115873020A (zh) Ras抑制剂
US10399970B2 (en) Pyrridinobenzodiazepine and benzopyrridodiazecine compounds
CN113498342A (zh) 参与协同结合的化合物和其用途
US9999625B2 (en) Pyrrolobenzodiazepine compounds
CN112341521A (zh) 一种小分子活性化合物及其抗体偶联物、其制备方法和医药用途
JP2021512103A (ja) Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
JP2022529583A (ja) 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス－ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体
CN114269720A (zh) 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
EP4359414A1 (en) Bifunctional folate receptor binding compounds
CN107660208B (zh) 包含cti药效团的双功能细胞毒性剂
EA040562B1 (ru) Соединения пиперидинобензодиазепина, обладающие антипролиферативной активностью
HK40076306A (en) Ras inhibitors
GB2567126A (en) PBC compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180928